Disc Medicine finalised the pivotal Phase III trial design of bitopertin in erythropoietic protoporphyria (EPP) with the FDA ...

By Vijay Kumar Malesu Study identifies chlorcyclizine as a potential treatment to reduce protoporphyrin-IX accumulation and ...

Disc Medicine has finalized the design of the confirmatory trial for its rare blood disorder drug candidate, adding a ...

Improved methods for the detection of heme and protoporphyrin IX adducts and quantification of heme B from cytochrome P450 containing systems. Validated extended multiplexed LC-MS/MS assay for the ...

[14] 5-ALA has no photosensitivity, but it can produce strong photosensitizer protoporphyrin IX after a series of transformations in cells. Related clinical studies have confirmed that 5-ALA can ...

Detailed price information for Disc Medicine Inc (IRON-Q) from The Globe and Mail including charting and trades.